Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Blood (2024) 144 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2024-209537

Published: 2024

Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Blood (2024) 144 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2024-205465

Published: 2024

Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood (2024) 144 (Supplement 1): 733.

https://doi.org/10.1182/blood-2024-209097

Published: 2024

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Blood (2023) 142 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2023-182220

Published: 2023

Journal Articles

Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study

Jorge Cortes, Fabian Lang, Delphine Rea, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P Hughes, Jeroen J.W.M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessami Sanchez-Olle, Nathalie Pognan, Jomy Jose, Matthias Hoch, Michael Mauro

Blood (2023) 142 (Supplement 1): 868.

https://doi.org/10.1182/blood-2023-189270

Published: 2023

Journal Articles

Impact of Hemodilution on Measurable Residual Disease Measured Via Flow-Cytometry in Acute Myeloid Leukemia Analyzed Using Subsequent Pulls

Jesse M. Tettero, Maaike Heidinga, Tim R. Mocking, Glenn Fransen, Ezra S Beerman, Angèle Kelder, Willemijn Scholten, Alexander N. Snel, Lok Lam Ngai, Costa Bachas, Arjan A. Van de Loosdrecht, Gert Ossenkoppele, David C. de Leeuw, Jeroen J.W.M. Janssen, Jacqueline Cloos

Blood (2023) 142 (Supplement 1): 1559.

https://doi.org/10.1182/blood-2023-179242

Published: 2023

Journal Articles

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Dragana Milojkovic, Nicole Blijlevens, Yok-Lam Kwong, Uzma Zaidi, Fausto Castagnetti, Paolo Gallipoli, Maria Cristina Miggiano, Peter E Westerweel, Melissa Chen, M. Carmen Garcia Hernandez, William J. Kell, Pankit Vachhani, Neha Agarwal, Alessandra Colasante, Sridhar Meka, Aoife Smyth, Germano Ferreira, Jeroen J.W.M. Janssen

Blood (2023) 142 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2023-181937

Published: 2023

Journal Articles

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Blood (2023) 142 (Supplement 1): 2916.

https://doi.org/10.1182/blood-2023-173149

Published: 2023

Journal Articles

Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

Camille C.B. Kockerols, Peter JM Valk, Nicole M A Blijlevens, Jan J. Cornelissen, Avinash G. Dinmohamed, Inge Geelen, Mels Hoogendoorn, Jeroen J.W.M. Janssen, Laura G.M. Daenen, Bert A. van der Reijden, Peter E. Westerweel

Blood (2022) 140 (Supplement 1): 3887–3888.

https://doi.org/10.1182/blood-2022-168722

Published: 2022

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

Man Wai Tang, Deborah van der Tuin, Mesire Aydin, Jarom Heijmans, Arjan A. van de Loosdrecht, Ellen Meijer, Caroline E. Rutten, Marielle Wondergem, Jeroen J.W.M. Janssen, Marjolein Donker, Mette D. Hazenberg, Sonja Zweegman, Bart J. Biemond, David C. de Leeuw, Erfan Nur

Blood (2022) 140 (Supplement 1): 3287–3289.

https://doi.org/10.1182/blood-2022-163042

Published: 2022

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 2126–2129.

https://doi.org/10.1182/blood-2022-157684

Published: 2022

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

Indoleamine 2,3-Dioxygenase (IDO1) Levels and Activity Are Increased in Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Correlate with Molecular Response to Nilotinib Therapy

Sieghart Sopper, PhD, Satu Mustjoki, MD PhD, Gunther Gastl, Prof., Dr., Zlatko Trajanoski, Prof. Dr., Frank Giles, MD MB, Andreas Hochhaus, MD, Simon Geisler, Dietmar Fuchs, Prof. Dr., Dominik Wolf, MD, Jeroen J.W.M. Janssen, MD PhD

Blood (2016) 128 (22): 1912.

https://doi.org/10.1182/blood.V128.22.1912.1912

Published: 2016

Journal Articles

CML Treatment in Dutch Hospitals with Low Patient Volumes Is Associated with a Substandard Quality of Molecular Response Monitoring

Inge G.P. Geelen, MD, Noortje Thielen, MD PhD, Jeroen J.W.M. Janssen, MD PhD, Tanja Roosma, Otto Visser, MD PhD, Jan J. Cornelissen, MD PhD, Peter E. Westerweel, MD PhD

Blood (2016) 128 (22): 1913.

https://doi.org/10.1182/blood.V128.22.1913.1913

Published: 2016

Journal Articles

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML.

Jeroen J.W.M. Janssen, MD, Wendy Deenik, Karlijn G.M. Smolders, Monique Terwijn, Angele Kelder, J. J. Cornelissen, Gerrit-Jan Schuurhuis, Gert J. Ossenkoppele

Blood (2009) 114 (22): 3245.

https://doi.org/10.1182/blood.V114.22.3245.3245

Published: 2009

Journal Articles

Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression

Marielle J. Wondergem, Servi J.C. Stevens, Jeroen J.W.M. Janssen, Joost J. Oudejans, Gert J. Ossenkoppele, Jaap M. Middeldorp, Sonja Zweegman

Blood (2008) 111 (3): 1739.

https://doi.org/10.1182/blood-2007-09-111534

Published: 2008

Journal Articles

High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.

Martine E.D. Chamuleau, MD, Arjan A. Van de Loosdrecht, MD, PhD, Corine J. Hess, MD, Jeroen J.W.M. Janssen, MD, Adri Zevenbergen, Ruud Delwel, PhD, Peter J.M. Valk, PhD, Bob Lowenberg, MD, PhD, Gert J. Ossenkoppele, MD, PhD

Blood (2007) 110 (11): 4297.

https://doi.org/10.1182/blood.V110.11.4297.4297

Published: 2007

NARROW

Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Impact of Hemodilution on Measurable Residual Disease Measured Via Flow-Cytometry in Acute Myeloid Leukemia Analyzed Using Subsequent Pulls

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study

Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Indoleamine 2,3-Dioxygenase (IDO1) Levels and Activity Are Increased in Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Correlate with Molecular Response to Nilotinib Therapy

CML Treatment in Dutch Hospitals with Low Patient Volumes Is Associated with a Substandard Quality of Molecular Response Monitoring

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML.

Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression

High INDO (Indoleamine 2,3-Dioxygenase) mRNA Level in Blasts of Acute Myeloid Leukemic Patients Predicts Poor Clinical Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only